Abnormalities in the Recirculation Phase of Contrast Agent Bolus Passage in Cerebral Gliomas: Comparison with Relative Blood Volume and Tumor Grade

References

1. ↵
   Endrich B, Vaupel P. The role of the micro-circulation in the treatment of malignant tumours: facts and fiction. In: Molls M, Vaupel P, eds. Blood Perfusion and Microenvironment of Human Tumours. Berlin-Heidelberg: Springer; 1998:19–39
2. ↵
   Amoroso A, Del Porto F, Di Monaco C, Manfredini P, Afeltra A. Vascular endothelial growth factor: a key mediator of neoangiogenesis—a review. Eur Rev Med Pharmacol Sci 1997;1:17–25

   PubMed
3. ↵
   Shweiki D, Neeman M, Itin A, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci U S A 1995;92:768–7

   Abstract/FREE Full Text
4. ↵
   Jensen RL. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. [See comments 1998;49:196.] Surg Neurol 1998;49:189–195

   CrossRefPubMedWeb of Science
5. ↵
   Brem S, Cotran R, Folkman J. Tumour angiogenesis: a quantitative method for histological grading. J Natl Cancer Inst 1972;28:347–356
6. ↵
   Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41–51

   PubMedWeb of Science
7. ↵
   Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol 1996;167–190
8. ↵
   Dachs GU, Chaplin DJ. Microenvironmental control of gene expression: implications for tumor angiogenesis, progression, and metastasis. Semin Radiat Oncol 1998;8:208–216

   CrossRefPubMedWeb of Science
9. ↵
   Winlaw DS. Angiogenesis in the pathobiology and treatment of vascular and malignant diseases. Ann Thorac Surg 1997;64:1204–1211

   CrossRefPubMed
10. ↵
    Miyati T, Banno T, Mase M, et al. Dual dynamic contrast-enhanced MR imaging. J Magn Reson Imaging 1997;7:230–235

    PubMed
11. Maeda M, Itoh S, Kimura H, et al. Vascularity of meningiomas and neuromas: assessment with dynamic susceptibility-contrast MR imaging. AJR Am J Roentgenol 1994;163:181–186

    PubMed
12. ↵
    Aronen HJ, Glass J, Pardo FS, et al. Echo-planar MR cerebral blood volume mapping of gliomas: clinical utility. Acta Radiol 1995;36:520–528.

    PubMed
13. ↵
    Griebel J, Mayr NA, de Vries A, et al. Assessment of tumor microcirculation: a new role of dynamic contrast MR imaging. J Magn Reson Imaging 1997;7:111–119

    PubMed
14. ↵
    Cha S, Knopp EA, Johnson G, et al. Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 2000;21:881–890

    Abstract/FREE Full Text
15. ↵
    Roberts HC, Roberts TP, Brasch RC, Dillon WP. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000;21:891–889

    Abstract/FREE Full Text
16. ↵
    Kassner A, Annesley DJ, Zhu XP, et al. Abnormalities of the contrast re-circulation phase in cerebral tumors demonstrated using dynamic susceptibility contrast-enhanced imaging: a possible marker of vascular tortuosity. J Magn Reson Imaging 2000;11:103–113

    CrossRefPubMed
17. ↵
    Kleihues P, Burger PC, Scheithauer BW. Histological Classification of CNS Tumours of the Central Nervous System, 2nd ed. Berlin: Springer-Verlag; 1993: 1–105
18. ↵
    Weisskoff RM, Zuo CS, Boxerman JL, Rosen BR. Microscopic susceptibility variation and transverse relaxation: theory and experiment. Magn Reson Med 1994;31:601–610

    PubMedWeb of Science
19. ↵
    Boxerman J, Hamberg L, Rosen B, Weisskoff R. MR contrast due to intravascular magnetic susceptibility perturbations. Mag Reson Med 1995;34:555–566

    CrossRefPubMedWeb of Science
20. ↵
    Rosen BR, Belliveau JW, Vevea JM, Brady TJ. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990;14:249–265

    PubMedWeb of Science
21. ↵
    Boxerman JL, Rosen BR, Weisskoff RM. Signal-to-noise analysis of cerebral blood volume maps from dynamic NMR imaging studies. J Magn Reson Imaging 1997;7:528–537

    PubMed
22. ↵
    Benner T, Heiland S, Erb G, Forsting M, Sartor K. Accuracy of gamma-variate fits to concentration-time curves from dynamic susceptibility-contrast enhanced MRI: influence of time resolution, maximal signal drop and signal to noise. Magn Reson Imaging 1997;15:307–317

    CrossRefPubMed
23. ↵
    Buckley DL, Kerslake RW, Blackband SJ, Horsman A. Quantitative analysis of multi-slice Gd-DTPA enhanced dynamic MR images using a Simplex minimization procedure. Magn Reson Med 1994;32:646–651

    PubMed
24. ↵
    Press W, Teukolsky S, Vetterling W, Flannery B. Minimization or maximization of functions. In: Numerical Recipes in C: The Art of Scientific Computing. New York: Cambridge University Press; 1992:394–454
25. ↵
    Rosen BR, Belliveau JW, Aronen HJ, et al. Susceptibility contrast imaging of cerebral blood volume: human experience. Magn Reson Med 1991;22:293–299

    PubMedWeb of Science
26. ↵
    Mayr N, Hawighorst H, Yuh W, et al. MR microcirculation assessment in cervical cancer: correlations with histomorphological tumour markers and clinical outcome. J Magn Reson Imaging 1999;10:267–276

    CrossRefPubMedWeb of Science
27. ↵
    Konerding M, van Ackern C, Fait E, Steinberg F, Streffer C. Morphological aspects of tumour angiogenesis and microcirculation. In: Molls M, Vaupel P, eds. Blood Perfusion and Microenvironment of Human Tumours. Berlin-Heidelberg: Springer; 1998: 5–17
28. ↵
    Plate K, Mennel H. Vascular morphology and angiogenesis in glial tumours. Exp Toxic Pathol 1995;47:89–94

    CrossRefPubMedWeb of Science
29. ↵
    Plate KH, Risau W. Angiogenesis in malignant gliomas. Glia 1995;15:339–347

    CrossRefPubMedWeb of Science
30. ↵
    Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998;49:407–424

    CrossRefPubMedWeb of Science
31. Mayr NA, Yuh WT, Zheng J, et al. Prediction of tumor control in patients with cervical cancer: analysis of combined volume and dynamic enhancement pattern by MR imaging. AJR Am J Roentgenol 1998;170:177–182

    PubMedWeb of Science
32. Wenz F, Rempp K, Hess T, et al. Effect of radiation on blood volume in low-grade astrocytomas and normal brain tissue: quantification with dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 1996;166:187–193

    PubMed
33. ↵
    Bruening R, Kwong KK, Vevea MJ, et al. Echo-planar MR determination of relative cerebral blood volume in human brain tumors: T1 versus T2 weighting [see comments]. AJNR Am J Neuroradiol 1996;17:831–840

    Abstract
34. ↵
    Siegal T, Rubinstein R, Tzuk-Shina T, Gomori JM. Utility of relative cerebral blood volume mapping derived from perfusion magnetic resonance imaging in the routine follow up of brain tumors. J Neurosurg 1997;86:22–27

    PubMedWeb of Science
35. ↵
    Hacklander T, Reichenbach JR, Modder U. Comparison of cerebral blood volume measurements using the T1 and T2* methods in normal human brains and brain tumors. J Comput Assist Tomogr 1997;21:857–866

    CrossRefPubMed
36. ↵
    Edelman RR, Mattle HP, Atkinson DJ, et al. Cerebral blood flow: assessment with dynamic contrast-enhanced T2*-weighted MR imaging at 1.5 T. Radiology 1990;176:211–220

    PubMed
37. ↵
    Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029–1039

    PubMedWeb of Science
38. ↵
    Jayson G, Mulatero C, Ranson M, et al. Anti-VEGF antibody HuMV833: an EORTC biological treatment development group phase I toxicity: pharmacokinetic and pharmacodynamic study. In: Proceedings of the American Society of Clinical Oncology, San Francisco, Ca, 2001